Nasdaq · Healthcare
ANI PHARMACEUTICALS INC (ANIP)
As-reported financials and recent SEC filings for ANI PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$883.4M
Net income
$78.3M
Net margin
8.9%
Diluted EPS
$3.32
ROE
14.5%
P/E (TTM)
21.6×
Market cap
$1.92B
Debt / equity
0.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $111.1M | $584,000 | $47.0M | $-35.3M | $-39.8M |
| Net income | $78.3M | $-18.5M | $18.8M | $-47.9M | $-42.6M |
| Diluted EPS | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-15
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-09
View on EDGAR →1442026-06-08
View on EDGAR →Go deeper on ANIP
Search ANI PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.